Last reviewed · How we verify

Yunhe Pharmaceutical (Tianjin) Co., Ltd — Portfolio Competitive Intelligence Brief

Yunhe Pharmaceutical (Tianjin) Co., Ltd pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
INR101 INR101 phase 3 Vitamin K antagonist VKORC1 Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Joon Bum Kim · 1 shared drug class
  2. Population Health Research Institute · 1 shared drug class
  3. US Department of Veterans Affairs · 1 shared drug class
  4. University Hospital, Bonn · 1 shared drug class
  5. University Hospital, Limoges · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Yunhe Pharmaceutical (Tianjin) Co., Ltd:

Cite this brief

Drug Landscape (2026). Yunhe Pharmaceutical (Tianjin) Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yunhe-pharmaceutical-tianjin-co-ltd. Accessed 2026-05-17.

Related